TRML Tourmaline Bio Inc

Price (delayed)

$15.41

Market cap

$395.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.08

Enterprise value

$297.08M

talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic ...

Highlights
TRML's equity has soared by 119% year-on-year and by 73% since the previous quarter
TRML's EPS has surged by 84% year-on-year and by 54% since the previous quarter

Key stats

What are the main financial stats of TRML
Market
Shares outstanding
25.65M
Market cap
$395.21M
Enterprise value
$297.08M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$32.94M
EBITDA
-$33.37M
Free cash flow
-$25.84M
Per share
EPS
-$4.08
Free cash flow per share
-$1.07
Book value per share
$13.81
Revenue per share
$0
TBVPS
$14.91
Balance sheet
Total assets
$359.17M
Total liabilities
$5.03M
Debt
$376,000
Equity
$354.14M
Working capital
$295.27M
Liquidity
Debt to equity
0
Current ratio
62.17
Quick ratio
60.76
Net debt/EBITDA
2.94
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-15%
Return on equity
-15.5%
Return on invested capital
-24.9%
Return on capital employed
-9.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TRML stock price

How has the Tourmaline Bio stock price performed over time
Intraday
4.76%
1 week
1.31%
1 month
0.72%
1 year
-49.97%
YTD
-41.14%
QTD
19.83%

Financial performance

How have Tourmaline Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.85M
Net income
-$32.94M
Gross margin
N/A
Net margin
N/A
Tourmaline Bio's net income has increased by 22% QoQ
Tourmaline Bio's operating income has increased by 14% from the previous quarter

Growth

What is Tourmaline Bio's growth rate over time

Valuation

What is Tourmaline Bio stock price valuation
P/E
N/A
P/B
1.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
TRML's EPS has surged by 84% year-on-year and by 54% since the previous quarter
TRML's equity has soared by 119% year-on-year and by 73% since the previous quarter
The price to book (P/B) is 25% lower than the last 4 quarters average of 1.5

Efficiency

How efficient is Tourmaline Bio business performance
The company's return on assets has shrunk by 154% YoY but it rose by 38% QoQ
Tourmaline Bio's ROE has plunged by 138% YoY but it has increased by 39% from the previous quarter
TRML's return on invested capital is up by 39% since the previous quarter

Dividends

What is TRML's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TRML.

Financial health

How did Tourmaline Bio financials performed over time
The total assets has soared by 108% YoY and by 71% from the previous quarter
TRML's total liabilities has plunged by 54% YoY and by 4.2% from the previous quarter
The company's debt is 100% lower than its equity
TRML's equity has soared by 119% year-on-year and by 73% since the previous quarter
The company's debt to equity has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.